SUBSCRIBE
SUBSCRIBE

Brandon May

FDA
Houston’s Hope BioSciences Highlights Texas’ Hotbed Status
Texas is quickly becoming a hotbed of biopharmaceutical activities, with Houston being one of the two top cities in the state that is leading the way.
April 28, 2021
 · 
3 min read
 · 
Brandon May
BioMidwest
Alpha 9, Engage Tech Raise Funds for Cancer Therapeutics, Improved Patient Journey
Alpha-9 Theranostics announced the closing of an $11 million Series A financing today, while Engage Technologies also announced it has raised money in a Series A round, funding that came in at a tune of $15 million.
April 28, 2021
 · 
2 min read
 · 
Brandon May
Reproxalap showing positive results in allergy-rel
Drug Development
Aldeyra’s Small Molecule, Reproxalap, Significantly Helps Allergy-Related Eye Symptoms
Top-line results from the Phase III INVIGORATE trial show Aldeyra Therapeutics’, reproxalap, significantly reduced ocular itching in patients with allergic conjunctivitis.
April 27, 2021
 · 
3 min read
 · 
Brandon May
FDA
Trying Again, Enzyvant Resubmits BLA for Pediatric Congenital Athymia Drug
Enzyvant has resubmitted its Biologics Licensing Application to the U.S. FDA for its tissue-based regenerative pediatric congenital athymia therapy RVT-802.
April 27, 2021
 · 
2 min read
 · 
Brandon May
Policy
Ocugen-Bharat Biotech Vaccine Shows Efficacy Against B.1.617 Variant
A new study published online has provided some hope for the citizens in India, with researchers suggesting that the Covaxin vaccine, developed by Bharat Biotech and Pennsylvania-based Ocugen, could neutralize the SARS-CoV-2 variant leading the second wave in the country.
April 26, 2021
 · 
3 min read
 · 
Brandon May
Business
Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company’s work in the development of protein-based treatments for COVID-19 and various cancers.
April 23, 2021
 · 
3 min read
 · 
Brandon May
Business
“Long Haul” COVID-19 Associated With More Medication Use, Higher Risk of Death
A new study suggests that many patients with long-term COVID-19 symptoms still experience health issues six months following infection, are survivors with “long haul” disease have a greater risk of dying and use a more significant number of medications than patients who have fully recovered from the virus.
April 23, 2021
 · 
3 min read
 · 
Brandon May
Pharm Country
Aptorum Enters Agreement With Yale to Develop, Investigate Novel Immunomodulators
Clinical-stage biopharmaceutical company, Aptorum Group Limited, announced today that it has entered into a material transfer and option agreement with Yale University to study preclinical stage novel immunomodulators targeting autoimmune and oncology diseases.
April 22, 2021
 · 
2 min read
 · 
Brandon May
BioCapital
Seed Health and Anavo Therapeutics Launch With Millions in in Early Financings
New Series A financing rounds have been announced in the last two days, with Seed Health leading the pack followed by Anavo Therapeutics.
April 22, 2021
 · 
3 min read
 · 
Brandon May
Policy
Researchers Get to Work on Opioid Overuse Vaccine With $25 Million NIH Grant
A $25 million grant from the National Institutes of Health Helping to End Addiction Long-term Initiative (HEAL) is funding new research to develop a vaccine that may help patients overcome their addiction to opioids, a class of highly addictive pain medications.
April 21, 2021
 · 
2 min read
 · 
Brandon May
Genetown
Beam’s New CRISPR Base Editing Tool Targets Sickle Cell Mutation
Beam Therapeutics has recently unveiled a new CRISPR base editing tool to target sickle cell mutations, a promising approach that holds substantial clinical value for patients with these blood disorders.
April 21, 2021
 · 
3 min read
 · 
Brandon May
Drug Development
KalVista’s Hereditary Angioedema Trial On Hold as FDA Requests Additional Data
The agency is requesting additional information and analysis of preclinical studies regarding KVD824 before giving the go-ahead to the Phase II trial.
April 20, 2021
 · 
3 min read
 · 
Brandon May
Business
Tonix Seeks to Advance OyaGen’s COVID-19 Treatment Under New Global Licensing Deal
The companies also plan to develop the candidate for the treatment of other potential future viral diseases.
April 19, 2021
 · 
3 min read
 · 
Brandon May
Drug Development
Adagio Raises $336 Million to Support Development of COVID-19 Antibody Candidate
The new financing round was led by RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.
April 19, 2021
 · 
3 min read
 · 
Brandon May
Monkey-human hybrid Embryo
Monkey-Human Hybrid Research Offers Promise, but Sparks Ethical Debate
According to the researchers, monkey-human hybrid is the new hope. It will remove many experimental barriers. How this is going to happen, know that here.
April 16, 2021
 · 
4 min read
 · 
Brandon May
Load More